TY - JOUR AU - Coiffier, B. AU - Lepage, E. AU - Brière, J. AU - Herbrecht, R. AU - Tilly, H. AU - Bouabdallah, R. PY - 2002 DA - 2002// TI - CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-Cell lymphoma JO - The N Engl J Med. VL - 346 UR - https://doi.org/10.1056/NEJMoa011795 DO - 10.1056/NEJMoa011795 ID - Coiffier2002 ER - TY - JOUR AU - Xu, Y. AU - Xie, L. AU - Zhang, E. AU - Gao, W. AU - Wang, L. AU - Cao, Y. PY - 2019 DA - 2019// TI - Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera® JO - MAbs. VL - 11 UR - https://doi.org/10.1080/19420862.2019.1578147 DO - 10.1080/19420862.2019.1578147 ID - Xu2019 ER - TY - JOUR AU - Pfreundschuh, M. AU - Kuhnt, E. AU - Trümper, L. AU - Österborg, A. AU - Trneny, M. AU - Shepherd, L. PY - 2011 DA - 2011// TI - CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70235-2 DO - 10.1016/S1470-2045(11)70235-2 ID - Pfreundschuh2011 ER - TY - JOUR AU - Pfreundschuh, M. AU - Truemper, L. AU - Gill, D. AU - Osterborg, A. AU - Pettengell, R. AU - Trneny, M. PY - 2004 DA - 2004// TI - First analysis of the Completed Mabthera International (Mint) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease JO - Blood. VL - 104 UR - https://doi.org/10.1182/blood.V104.11.157.157 DO - 10.1182/blood.V104.11.157.157 ID - Pfreundschuh2004 ER -